NCT00292760View on ClinicalTrials.gov

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Chronic Lymphocytic Leukaemia
Interventions
DRUG

Alemtuzumab

DRUG

Methyprednisolone

All Listed Sponsors
lead

Royal Marsden NHS Foundation Trust

OTHER